JP2019506367A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506367A5 JP2019506367A5 JP2018529633A JP2018529633A JP2019506367A5 JP 2019506367 A5 JP2019506367 A5 JP 2019506367A5 JP 2018529633 A JP2018529633 A JP 2018529633A JP 2018529633 A JP2018529633 A JP 2018529633A JP 2019506367 A5 JP2019506367 A5 JP 2019506367A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- modulator
- oxy
- pain
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 108
- 238000000034 method Methods 0.000 claims description 66
- 239000000203 mixture Substances 0.000 claims description 59
- 125000005843 halogen group Chemical group 0.000 claims description 51
- 208000002193 Pain Diseases 0.000 claims description 44
- 230000036407 pain Effects 0.000 claims description 40
- 150000001875 compounds Chemical class 0.000 claims description 21
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 208000004296 neuralgia Diseases 0.000 claims description 12
- 208000021722 neuropathic pain Diseases 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- -1 R 24 Chemical compound 0.000 claims description 10
- 239000012453 solvate Substances 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 7
- 229920006395 saturated elastomer Polymers 0.000 claims description 7
- 125000006413 ring segment Chemical group 0.000 claims description 6
- 208000001294 Nociceptive Pain Diseases 0.000 claims description 5
- SKXPEZRPXUSJHY-IKJXHCRLSA-N (5r)-5-ethyl-3-[2-[[3-methyl-3-(trifluoromethyl)-1h-2-benzofuran-5-yl]oxy]pyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(COC2(C)C(F)(F)F)C2=C1 SKXPEZRPXUSJHY-IKJXHCRLSA-N 0.000 claims description 4
- XYISZEPLGKRZAR-NYRJJRHWSA-N (5r)-5-ethyl-3-[6-[[3-methyl-3-(trifluoromethyl)-1h-2-benzofuran-5-yl]oxy]pyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(COC2(C)C(F)(F)F)C2=C1 XYISZEPLGKRZAR-NYRJJRHWSA-N 0.000 claims description 4
- BLJABDKRDIIYLJ-UHFFFAOYSA-N 3-[6-[(3-tert-butyl-1,3-dihydro-2-benzofuran-5-yl)oxy]pyridin-3-yl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound C1=C2C(C(C)(C)C)OCC2=CC=C1OC(N=C1)=CC=C1N1C(=O)NC(C)(C)C1=O BLJABDKRDIIYLJ-UHFFFAOYSA-N 0.000 claims description 4
- PFWPHOLELOXFFV-UHFFFAOYSA-N 5,5-dimethyl-3-[2-[[3-methyl-3-(trifluoromethyl)-1h-2-benzofuran-5-yl]oxy]pyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O=C1C(C)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(COC2(C)C(F)(F)F)C2=C1 PFWPHOLELOXFFV-UHFFFAOYSA-N 0.000 claims description 4
- NKMHTNGMJVHRTM-UHFFFAOYSA-N 5,5-dimethyl-3-[6-[[3-methyl-3-(trifluoromethyl)-1h-2-benzofuran-5-yl]oxy]pyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1C(C)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(COC2(C)C(F)(F)F)C2=C1 NKMHTNGMJVHRTM-UHFFFAOYSA-N 0.000 claims description 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 4
- 206010065390 Inflammatory pain Diseases 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- MCSCOJJHSDROQX-QGZVFWFLSA-N (5r)-3-[2-[(2,2-difluoro-7-methyl-1,3-benzodioxol-4-yl)oxy]pyrimidin-5-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical class O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(C)C2=C1OC(F)(F)O2 MCSCOJJHSDROQX-QGZVFWFLSA-N 0.000 claims description 2
- SHSPZEJVBTZRAQ-OAQYLSRUSA-N (5r)-3-[6-[(3,3-dimethyl-1h-2-benzofuran-5-yl)oxy]pyridin-3-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(COC2(C)C)C2=C1 SHSPZEJVBTZRAQ-OAQYLSRUSA-N 0.000 claims description 2
- OWZHSHKAPQCKHB-MRXNPFEDSA-N (5r)-3-[6-[(3,3-dimethyl-1h-2-benzofuran-5-yl)oxy]pyridin-3-yl]-5-ethylimidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(COC2(C)C)C2=C1 OWZHSHKAPQCKHB-MRXNPFEDSA-N 0.000 claims description 2
- LSOZZXGDMKCFRV-MRXNPFEDSA-N (5r)-5-ethyl-3-(2-spiro[1h-2-benzofuran-3,1'-cyclobutane]-5-yloxypyrimidin-5-yl)imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(COC23CCC3)C2=C1 LSOZZXGDMKCFRV-MRXNPFEDSA-N 0.000 claims description 2
- GANVXLQPVDRZDP-QGZVFWFLSA-N (5r)-5-ethyl-3-(6-spiro[1h-2-benzofuran-3,1'-cyclobutane]-5-yloxypyridin-3-yl)imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(COC23CCC3)C2=C1 GANVXLQPVDRZDP-QGZVFWFLSA-N 0.000 claims description 2
- LWGBRPAONSBLOJ-CYBMUJFWSA-N (5r)-5-ethyl-3-[2-(7-methylspiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(C)C2=C1C1(CC1)CO2 LWGBRPAONSBLOJ-CYBMUJFWSA-N 0.000 claims description 2
- AMAOXEGBJHLCSF-CQSZACIVSA-N (5r)-5-ethyl-3-[6-(3-methoxy-4-methylphenoxy)pyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(C)C(OC)=C1 AMAOXEGBJHLCSF-CQSZACIVSA-N 0.000 claims description 2
- NPNNMBCPDXXEAG-CQSZACIVSA-N (5r)-5-ethyl-3-[6-(7-methylspiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yl)oxypyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(C)C2=C1C1(CC1)CO2 NPNNMBCPDXXEAG-CQSZACIVSA-N 0.000 claims description 2
- JFNGOQQEZATLIZ-CYBMUJFWSA-N (5r)-5-ethyl-3-[6-[4-methyl-3-(trifluoromethoxy)phenoxy]pyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(C)C(OC(F)(F)F)=C1 JFNGOQQEZATLIZ-CYBMUJFWSA-N 0.000 claims description 2
- VJORKOHZKOIAOJ-HXUWFJFHSA-N (5r)-5-ethyl-5-methyl-3-[2-(7-methylspiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(C)C2=C1C1(CC1)CO2 VJORKOHZKOIAOJ-HXUWFJFHSA-N 0.000 claims description 2
- OYFGQTVERWVDGF-OAQYLSRUSA-N (5r)-5-ethyl-5-methyl-3-[2-[(3,3,7-trimethyl-2h-1-benzofuran-4-yl)oxy]pyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(C)C2=C1C(C)(C)CO2 OYFGQTVERWVDGF-OAQYLSRUSA-N 0.000 claims description 2
- DZJBKKVCXVSFHQ-QGZVFWFLSA-N (5r)-5-ethyl-5-methyl-3-[2-[4-methyl-3-(trifluoromethoxy)phenoxy]pyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(C)C(OC(F)(F)F)=C1 DZJBKKVCXVSFHQ-QGZVFWFLSA-N 0.000 claims description 2
- CWHUKRBJRARMCX-OAQYLSRUSA-N (5r)-5-ethyl-5-methyl-3-[6-(7-methylspiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yl)oxypyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(C)C2=C1C1(CC1)CO2 CWHUKRBJRARMCX-OAQYLSRUSA-N 0.000 claims description 2
- QJEJEPKGWPVGQU-UHFFFAOYSA-N 3-methyl-4-(6-spiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yloxypyridin-3-yl)-1h-1,2,4-triazol-5-one Chemical compound CC1=NNC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1C1(CC1)CO2 QJEJEPKGWPVGQU-UHFFFAOYSA-N 0.000 claims description 2
- SXVVXFKHWPURFB-UHFFFAOYSA-N 3-methyl-4-[6-(7-methylspiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yl)oxypyridin-3-yl]-1h-1,2,4-triazol-5-one Chemical compound CC1=NNC(=O)N1C(C=N1)=CC=C1OC1=CC=C(C)C2=C1C1(CC1)CO2 SXVVXFKHWPURFB-UHFFFAOYSA-N 0.000 claims description 2
- ABBBYWZTLYAUOM-UHFFFAOYSA-N 5,5-dimethyl-3-(6-spiro[1h-2-benzofuran-3,1'-cyclobutane]-5-yloxypyridin-3-yl)imidazolidine-2,4-dione Chemical compound O=C1C(C)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(COC23CCC3)C2=C1 ABBBYWZTLYAUOM-UHFFFAOYSA-N 0.000 claims description 2
- JYHHQTRVJFMEGR-UHFFFAOYSA-N 5,5-dimethyl-3-[2-(7-methylspiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O1CC2(CC2)C2=C1C(C)=CC=C2OC(N=C1)=NC=C1N1C(=O)NC(C)(C)C1=O JYHHQTRVJFMEGR-UHFFFAOYSA-N 0.000 claims description 2
- RKJVNBMHIUOWSI-UHFFFAOYSA-N 5,5-dimethyl-3-[2-[4-methyl-3-(trifluoromethoxy)phenoxy]pyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound C1=C(OC(F)(F)F)C(C)=CC=C1OC1=NC=C(N2C(C(C)(C)NC2=O)=O)C=N1 RKJVNBMHIUOWSI-UHFFFAOYSA-N 0.000 claims description 2
- FTJZGRAFIVZFDZ-UHFFFAOYSA-N 5,5-dimethyl-3-[6-(7-methylspiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yl)oxypyridin-3-yl]imidazolidine-2,4-dione Chemical compound O1CC2(CC2)C2=C1C(C)=CC=C2OC(N=C1)=CC=C1N1C(=O)NC(C)(C)C1=O FTJZGRAFIVZFDZ-UHFFFAOYSA-N 0.000 claims description 2
- VXCFTYWNOQFXHH-UHFFFAOYSA-N 5,5-dimethyl-3-[6-[4-methyl-3-(trifluoromethoxy)phenoxy]pyridin-3-yl]imidazolidine-2,4-dione Chemical compound C1=C(OC(F)(F)F)C(C)=CC=C1OC1=CC=C(N2C(C(C)(C)NC2=O)=O)C=N1 VXCFTYWNOQFXHH-UHFFFAOYSA-N 0.000 claims description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 2
- 206010003011 Appendicitis Diseases 0.000 claims description 2
- PXFIECRVZMWQOW-UHFFFAOYSA-N CC1=C(C=C(C=C1)OC1=NC=C(C=N1)N1C(NC(C1)=O)=O)OC(F)(F)F Chemical compound CC1=C(C=C(C=C1)OC1=NC=C(C=N1)N1C(NC(C1)=O)=O)OC(F)(F)F PXFIECRVZMWQOW-UHFFFAOYSA-N 0.000 claims description 2
- 206010058019 Cancer Pain Diseases 0.000 claims description 2
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 208000004983 Phantom Limb Diseases 0.000 claims description 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 2
- 208000005298 acute pain Diseases 0.000 claims description 2
- 238000002266 amputation Methods 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 229960002870 gabapentin Drugs 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 229910001385 heavy metal Inorganic materials 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- 229940124583 pain medication Drugs 0.000 claims description 2
- 229960005489 paracetamol Drugs 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims description 2
- 229960001233 pregabalin Drugs 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 208000009935 visceral pain Diseases 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 3
- 208000019116 sleep disease Diseases 0.000 description 2
- 208000020685 sleep-wake disease Diseases 0.000 description 2
- 0 CN(CNC1(*)*)C1=O Chemical compound CN(CNC1(*)*)C1=O 0.000 description 1
- RDOXTESZEPMUJZ-UHFFFAOYSA-N COc1ccccc1 Chemical compound COc1ccccc1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022106247A JP2022141699A (ja) | 2015-12-10 | 2022-06-30 | 疼痛を治療するためのｋｖ３チャネルのモジュレーター |
| JP2024154042A JP2025003958A (ja) | 2015-12-10 | 2024-09-06 | 疼痛を治療するためのｋｖ３チャネルのモジュレーター |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1521751.6 | 2015-12-10 | ||
| GBGB1521751.6A GB201521751D0 (en) | 2015-12-10 | 2015-12-10 | Novel uses |
| PCT/GB2016/053879 WO2017098254A1 (en) | 2015-12-10 | 2016-12-09 | Modulators of kv3 channels to treat pain |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022106247A Division JP2022141699A (ja) | 2015-12-10 | 2022-06-30 | 疼痛を治療するためのｋｖ３チャネルのモジュレーター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019506367A JP2019506367A (ja) | 2019-03-07 |
| JP2019506367A5 true JP2019506367A5 (enExample) | 2020-01-30 |
| JP7149847B2 JP7149847B2 (ja) | 2022-10-07 |
Family
ID=55274489
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018529633A Active JP7149847B2 (ja) | 2015-12-10 | 2016-12-09 | 疼痛を治療するためのｋｖ３チャネルのモジュレーター |
| JP2022106247A Pending JP2022141699A (ja) | 2015-12-10 | 2022-06-30 | 疼痛を治療するためのｋｖ３チャネルのモジュレーター |
| JP2024154042A Pending JP2025003958A (ja) | 2015-12-10 | 2024-09-06 | 疼痛を治療するためのｋｖ３チャネルのモジュレーター |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022106247A Pending JP2022141699A (ja) | 2015-12-10 | 2022-06-30 | 疼痛を治療するためのｋｖ３チャネルのモジュレーター |
| JP2024154042A Pending JP2025003958A (ja) | 2015-12-10 | 2024-09-06 | 疼痛を治療するためのｋｖ３チャネルのモジュレーター |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11147813B2 (enExample) |
| EP (1) | EP3386506B1 (enExample) |
| JP (3) | JP7149847B2 (enExample) |
| KR (1) | KR102812887B1 (enExample) |
| CN (2) | CN118267386A (enExample) |
| AU (1) | AU2016367239B2 (enExample) |
| BR (1) | BR112018011700B1 (enExample) |
| DK (1) | DK3386506T3 (enExample) |
| EA (1) | EA038059B1 (enExample) |
| ES (1) | ES2974902T3 (enExample) |
| FI (1) | FI3386506T3 (enExample) |
| GB (1) | GB201521751D0 (enExample) |
| HR (1) | HRP20240497T1 (enExample) |
| HU (1) | HUE066879T2 (enExample) |
| IL (1) | IL259717B (enExample) |
| MX (1) | MX385578B (enExample) |
| PL (1) | PL3386506T3 (enExample) |
| PT (1) | PT3386506T (enExample) |
| SG (1) | SG11201804123VA (enExample) |
| WO (1) | WO2017098254A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201521751D0 (en) | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
| GB201613163D0 (en) | 2016-07-29 | 2016-09-14 | Autifony Therapeutics Ltd | Novel compounds |
| WO2018109484A1 (en) | 2016-12-16 | 2018-06-21 | Autifony Therapeutics Limited | Hydantoin modulators of kv3 channels |
| WO2018220762A1 (ja) * | 2017-05-31 | 2018-12-06 | 大塚製薬株式会社 | ピリミジン化合物 |
| US12358901B2 (en) | 2018-10-16 | 2025-07-15 | Autifony Therapeutics Limited | KV3 modulators |
| PL3867247T3 (pl) | 2018-10-16 | 2024-12-09 | Autifony Therapeutics Limited | Nowe związki |
| US20200131156A1 (en) * | 2018-10-30 | 2020-04-30 | H. Lundbeck A/S | ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS |
| WO2020111263A1 (en) | 2018-11-30 | 2020-06-04 | Otsuka Pharmaceutical Co., Ltd. | Heterocyclic compounds for the treatment of epilepsy |
| JP7522203B2 (ja) | 2020-02-06 | 2024-07-24 | アウトイフオンイ トヘラペウトイクス リミテッド | Ｋｖ３モジュレーター |
| CA3226856A1 (en) | 2021-08-10 | 2023-02-16 | Autifony Therapeutics Limited | Potassium channel modulators |
| CN113788741B (zh) * | 2021-09-28 | 2023-12-29 | 大连九信精细化工有限公司 | 一种制备2-环丙基苯酚衍生物的方法 |
| WO2024121552A1 (en) | 2022-12-06 | 2024-06-13 | Autifony Therapeutics Limited | Compounds for the treatment of centra nervous system disorders |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2300426A1 (en) | 2008-06-06 | 2011-03-30 | UCB Pharma, S.A. | Compounds comprising a cyclobutoxy group |
| US8722695B2 (en) | 2009-12-11 | 2014-05-13 | Autifony Therapeutics Limited | Imidazolidinedione derivatives |
| DK2649066T3 (en) * | 2010-12-06 | 2016-01-11 | Autifony Therapeutics Ltd | Hydantoin derivatives using as KV3 inhibitors. |
| GB201209986D0 (en) | 2012-06-06 | 2012-07-18 | Autifony Therapeutics Ltd | Novel compounds |
| US9193704B2 (en) | 2011-06-07 | 2015-11-24 | Autifony Therapeutics Limited | Hydantoin derivatives as KV3 inhibitors |
| IN2014CN04014A (enExample) | 2011-12-06 | 2015-07-10 | Autifony Therapeutics Ltd | |
| BR112014028718A2 (pt) | 2012-05-22 | 2017-06-27 | Autifony Therapeutics Ltd | derivados de hidantoína como inibidores de kv3 |
| CN104334547B (zh) * | 2012-05-22 | 2017-06-06 | 奥蒂福尼疗法有限公司 | 作为kv3抑制剂的三唑类 |
| WO2013182851A1 (en) | 2012-06-06 | 2013-12-12 | Autifony Therapeutics Limited | Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required |
| GB201521751D0 (en) | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
| GB201522179D0 (en) | 2015-12-16 | 2016-01-27 | Autifony Therapeutics Ltd | Novel compounds |
-
2015
- 2015-12-10 GB GBGB1521751.6A patent/GB201521751D0/en not_active Ceased
-
2016
- 2016-12-09 HU HUE16813020A patent/HUE066879T2/hu unknown
- 2016-12-09 JP JP2018529633A patent/JP7149847B2/ja active Active
- 2016-12-09 WO PCT/GB2016/053879 patent/WO2017098254A1/en not_active Ceased
- 2016-12-09 DK DK16813020.1T patent/DK3386506T3/da active
- 2016-12-09 EP EP16813020.1A patent/EP3386506B1/en active Active
- 2016-12-09 MX MX2018007074A patent/MX385578B/es unknown
- 2016-12-09 CN CN202410102663.8A patent/CN118267386A/zh active Pending
- 2016-12-09 KR KR1020187017088A patent/KR102812887B1/ko active Active
- 2016-12-09 PL PL16813020.1T patent/PL3386506T3/pl unknown
- 2016-12-09 FI FIEP16813020.1T patent/FI3386506T3/fi active
- 2016-12-09 SG SG11201804123VA patent/SG11201804123VA/en unknown
- 2016-12-09 CN CN201680072639.8A patent/CN108472288B/zh active Active
- 2016-12-09 PT PT168130201T patent/PT3386506T/pt unknown
- 2016-12-09 ES ES16813020T patent/ES2974902T3/es active Active
- 2016-12-09 EA EA201891377A patent/EA038059B1/ru unknown
- 2016-12-09 AU AU2016367239A patent/AU2016367239B2/en active Active
- 2016-12-09 BR BR112018011700-5A patent/BR112018011700B1/pt active IP Right Grant
- 2016-12-09 HR HRP20240497TT patent/HRP20240497T1/hr unknown
- 2016-12-09 US US16/060,714 patent/US11147813B2/en active Active
-
2018
- 2018-05-30 IL IL259717A patent/IL259717B/en active IP Right Grant
-
2021
- 2021-09-10 US US17/472,493 patent/US11944623B2/en active Active
-
2022
- 2022-06-30 JP JP2022106247A patent/JP2022141699A/ja active Pending
-
2024
- 2024-01-30 US US18/427,639 patent/US20250017925A1/en not_active Abandoned
- 2024-09-06 JP JP2024154042A patent/JP2025003958A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019506367A5 (enExample) | ||
| JP6162144B2 (ja) | ４，４−二置換−１，４−ジヒドロピリミジン、及びｂ型肝炎の処置のための医薬としてのその使用 | |
| HRP20240497T1 (hr) | Modulatori kv3 kanala za liječenje boli | |
| US8796253B2 (en) | Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| JP6218260B2 (ja) | Ｊａｋ阻害剤としてのアミノピリミジニル化合物 | |
| JP6385954B2 (ja) | キナーゼ調節のための化合物および方法、ならびにその適応 | |
| US9290507B2 (en) | B-RAF kinase inhibitors | |
| US11292786B2 (en) | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | |
| JP2011503166A5 (enExample) | ||
| US8865703B2 (en) | Pyridyltriazoles | |
| JP6195684B2 (ja) | ピラゾール化合物及びｔ型カルシウムチャンネルブロッカーとしてのそれらの使用 | |
| JP2016523911A5 (enExample) | ||
| RU2019132212A (ru) | Селективные ингибиторы hdac6 | |
| JP2014516073A5 (enExample) | ||
| RU2016102137A (ru) | Первичные карбоксамиды в качестве ингибиторов bik | |
| JP2015520764A5 (enExample) | ||
| US20120264735A1 (en) | Tyrosine kinase inhibitors | |
| JP2013544873A5 (enExample) | ||
| WO2013057101A1 (de) | Substituierte oxadiazolylpyridinone und - pyridazinone als hif - hemmer | |
| EP3016934A2 (en) | Heteroaryl compounds useful as inhibitors of sumo activating enzyme | |
| EP2569312A1 (de) | Substituierte heterocyclylbenzyl-pyrazole und ihre verwendung | |
| WO2013011033A1 (de) | 3-(fluorvinyl)pyrazole und ihre verwendung | |
| RU2019117958A (ru) | Производные индола, полезные в качестве ингибиторов диацилглицерид-о-ацилтрансферазы 2 | |
| US20180243298A1 (en) | Trpv3 modulators | |
| JP2020520925A5 (enExample) |